Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hybrid ligand-binding (LB) LC-MS/MS protein quantitative assays involve a LB step for analyte enrichment that has less stringent requirements than the conventional LB assays. Herceptin™(trastuzumab) binding to HER2 extracellular domain was evaluated using on-bead and off-bead capture formats. The two formats yielded significantly different trastuzumab concentrations in human and monkey serum pharmacokinetic samples. Biotransformations, including deamidation of asparagine and isomerization of aspartic acid near the complementarity-determining regions of trastuzumab, had a profound impact on the LB step for analyte enrichment and trastuzumab quantification. Quantitative measurements were profoundly impacted by LB conditions in a hybrid LB LC-MS/MS protein assay due to biotransformations. Therefore, similar to conventional LB assays, binding conditions should be carefully evaluated during assay development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/bio-2018-0196 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping PFAS behavior via meta-analysis of soil dynamics, predictive modeling and policy integration.
Sci Total Environ
September 2025
University Hohenheim, Department of Process Analytics and Cereal Science, Stuttgart, 70599, Germany.
Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants with increasing prevalence in agricultural soils, primarily introduced through biosolid application, wastewater irrigation, and atmospheric deposition. This review provides a meta-analysis of terminologies across 145 peer-reviewed studies, identifying inconsistency in the classification of PFAS subgroups-such as "long-chain vs. short-chain," "precursors," and "emerging PFAS"-which hinders regulatory harmonization and model calibration.
View Article and Find Full Text PDFRecent Advances in Bioanalytical Methods for Quantification and Pharmacokinetic Analyses of Antibody-Drug Conjugates.
AAPS J
September 2025
Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 5A03, Bethesda, Maryland, 20892, USA.
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of therapeutics, uniquely combining the specificity of monoclonal antibodies with the potency of cytotoxic small-molecule payloads. Due to their inherent structural complexity and heterogeneous composition, accurate characterization and quantification of ADCs pose significant bioanalytical challenges. This review discusses recent advancements in bioanalytical methodologies, including ligand binding assays (LBAs), liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based approaches, and emerging hybrid LBA-LC-MS/MS platforms.
View Article and Find Full Text PDFA Novel Hybrid LC-MS/MS Methodology for the Quantitative Bioanalysis of Antibody-siRNA Conjugates.
Anal Chem
September 2025
Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States.
Small interfering RNA (siRNA) is a new class of oligonucleotide therapeutics that is rapidly growing in drug research and development for the treatment of various diseases. One major challenge for siRNA therapeutics is their inefficient delivery to target tissues by systemic administration. Antibody-siRNA conjugates (ARC) are being developed as a promising approach to enhancing the selectivity and delivery of siRNA payloads to target tissues.
View Article and Find Full Text PDFDefining Phytochemical Metabolomes of Somatic Hybrids L. (+) King ex Hook.f. (Gentianaceae) Using UHPLC-DAD-ESI-MS Analysis in Comparison to the Parental Species.
Molecules
August 2025
Department of Pharmaceutical Biology, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland.
Somatic hybridization represents a powerful tool for generating novel chemotypes with enhanced biosynthetic capabilities. This study provides the first comprehensive phytochemical characterization of interspecific somatic hybrids between L. and King ex Hook.
View Article and Find Full Text PDF6-Nitrodopamine Release From Mouse Seminal Vesicles Is Dependent on Endothelial Nitric Oxide Synthase (eNOS) Activation.
Pharmacol Res Perspect
October 2025
Department of Pharmacology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil.
Human seminal vesicles present basal release of epithelium-derived 6-nitrodopamine (6-ND) and this catecholamine potentiates noradrenaline-induced contractions. Since nitric oxide synthase (NOS) activation is a determining factor involved in 6-ND biosynthesis, this study aimed to investigate which NOS isoform is responsible for the 6-ND release in mouse isolated seminal vesicles (MISV). Male control, eNOS, NOS, iNOS, and e/n/iNOS mice were used.
View Article and Find Full Text PDF